Genomic testing for localized prostate cancer: an update

A relatively brief, current, full-text review article by Loeb and Ross is available on the Medscape web site and discusses the three currently available tests for assessment of genomic risk for men with localized forms of prostate cancer. … READ MORE …

Are genomic tests “up to snuff” for routine use in prognosis of prostate cancer risk?

The Intergroupe Coopérateur Francophone de Recherche en Onco-urologie (ICFuro) has just published a review of the available evidence on the clinical validity and utility of six prognostic biomarkers available for the assessment of prostate cancer-related risk. … READ MORE …

Can the Decipher test accurately project risk for metastasis post-surgery?

A newly published article in the Journal of Clinical Oncology suggests that the Decipher test may be able to predict risk for metastatic prostate at 10 years post-surgery. However, … READ MORE …

Is the Decipher test really as useful as it’s manufacturer seems to claim?

A newly published article in the journal PLoS One questions whether the Decipher® test (a 22-gene expression assay test) has actual clinical utility in helping physicians to make good decisions about the follow-up treatment of men with prostate cancer after an initial radical prostatectomy. … READ MORE …

Salvage radiation therapy and the need for concurrent ADT; the value of the Decipher test

A paper given at the recent annual meeting of the American Society for Radiation Ocology (ASTRO) suggests that the Decipher genomic classifier may help to distinguish between treatment options for men in need of salvage radiation therapy after first-line radical prostatectomy. … READ MORE …

Genomic classifier can help identify patients who may not need adjuvant radiation

A decision that tortures patients with adverse findings (positive margins, and/or stage T3/4) after prostatectomy is whether to jump into adjuvant radiation right away, or wait until PSA rises to 0.2 ng/ml before having salvage radiation. … READ M\ORE …

Medicare may soon cover Prolaris, Decipher tests for prostate cancer

Both Myriad Genetics and Genome DX Biosciences issued media releases today stating that Medicare contractors have issued draft coverage recommendations for tests used to assess the aggressiveness of prostate cancer based on genetic/genomic analyses of tissue from biopsy and post-surgical samples. … READ MORE …